UPPSALA, SWEDEN / ACCESSWIRE / November 28, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Continued sales growth and several commercial agreements signed!SEK tQ2 23/24Q2 22/23May-Oct 23/24May-Oct 22/23Full year 22/23Net sales2,5639614,3161,5063,383Operating profit (loss)-25,316-23,310-57,508-43,973-110,457Profit (loss) for the period-25,684-23,250-57,949-44,254-110,492Earnings per share, after...
Read moreBRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions, today announced the pricing of an underwritten public offering of 10,000,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each share of common stock (or...
Read more
FORT LAUDERDALE, FL / ACCESSWIRE / November 27, 2023 / Organicell Regenerative Medicine Inc, (OTCQB:OCEL) ("Organicell" or the "Company"), today announced that it is implementing a 1-for-200 Reverse Split of the Company's common stock (the "Reverse Split") effective as of the close of business on November 27, 2023. As a result, every 200 pre-Reverse Split shares of common stock outstanding will automatically combine into one new share of...
Read more
DehydraTECHTM-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus®:Sustained higher levels of semaglutide in blood;Faster achievement of peak drug delivery; andReduced side effects.KELOWNA, BC / ACCESSWIRE / November 27, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive interim results from a human pilot...
Read more
Joint solution enables healthcare providers to complete the longitudinal patient imaging recordANN ARBOR, MI and ALBUQUERQUE, NM / ACCESSWIRE / November 27, 2023 / Merge by Merative, an industry leader in medical imaging solutions, signed an agreement with Indica Labs, a leading provider of AI-powered digital pathology solutions. This partnership will enable healthcare organizations to seamlessly integrate digital pathology into Merge imaging...
Read more
UPPSALA, SE / ACCESSWIRE / November 24, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, publishes its interim report for the second quarter 2023/2024, on November 28 at 08:00 CET. The company invites you to a webcast on the same day at 15.00 CET.Anders Rylander, CEO, Warren Cresswell, President of Biovica Americas, Henrik Winther, SVP Business Development and Anders Morén, CFO will...
Read more
UPPSALA, SE / ACCESSWIRE / November 23, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The extra general meeting of Biovica International AB (the "Company") was held today on 23 November 2023 and the following resolution was passed by the meeting.Amendments of the articles of associationThe extra general meeting resolved, in accordance with the board of directors' proposal, to amend the limits of the articles of association...
Read more
Oral presentation outlines positive efficacy and safety dataConfirms interim data showing FG001 met primary endpoint, with cancer lit up in 16 /16 (100%) patients, and was very well toleratedSeveral applications for potential clinical benefit will be further exploredTopline phase IIb results of FG001 in high-grade glioma expected later in November 2023COPENHAGEN, DENMARK / ACCESSWIRE / November 21, 2023 // FluoGuide A/S ("FluoGuide" or the...
Read more
MANKATO, MN / ACCESSWIRE / November 21, 2023 / Digital Utilities Ventures, Inc. (OTC PINK:DUTV), announces that its planned future affiliate, Easy Energy Systems, Inc., will be exhibiting at the Organic Growers Show in Monterey on November 29-30. The summit provides growers firsthand knowledge and information in a variety of areas ranging from Agtech to food safety to sustainability. Through engaging educational sessions, insightful Keynote...
Read more
UPPSALA, SE / ACCESSWIRE / November 21, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that the Center for Medicare & Medicaid Services (CMS) after reviewing public comments, has agreed with the minority CDLT panel to crosswalk DiviTum TKa to reimbursement code 0058U. The comments CMS received included detailed information as to how these tests are similar enough to make...
Read more
Biostar Stem Cell Research Institute has received approval from Japan's Ministry of Health, Labor and Welfare to Treat Parkinson's Disease.The combination of intravenous and spinal cord cavity administration is expected to increase the effectiveness of the treatment. This therapy may also be effective for other incurable neurological diseases.The stem cells are cultured in special media produced by Nature Cell, an affiliate of Biostar Stem Cell...
Read more
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)The key secondary endpoints assessing symptom reduction, TSS50 and absolute change in TSS, showed significant improvements for intermediate-risk patients (pPelabresib plus ruxolitinib showed clinically meaningful anemia improvement versus placebo and...
Read more
1.0% Formulation Reached Primary Endpoint with Statistical SignificanceFull Analysis Identified Additional Efficacy SignalsTORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced favorable final results from a Phase 2b dose-ranging clinical study of the company's drug candidate, EB01 (daniluromer), as a...
Read more
Vironova BioAnalytics AB Acquired by an investor syndicate, led by Quatre Lab, to expand its TEM services for the pharmaceutical industry; to be rebranded as QuTEMSTOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2023 / Vironova BioAnalytics, a leading provider of transmission electron microscopy (TEM) services, is pleased to announce its acquisition led by QuatreLab (a quality control company created by Columbus Venture Partners) with the...
Read more
NEW YORK, NY / ACCESSWIRE / November 20, 2023 / Qrons Inc. (OTCQB:QRON) announced that Professor Shiri Navon-Venezia has agreed to join Qrons Scientific Advisory Board. Professor Venezia is Professor of Microbiology, Head of Bacterial Pathogens & Antibiotic Resistance Lab in Ariel University. Her areas of expertise are Pathogenesis of multidrug resistant bacteria, molecular mechanisms of antibiotic resistance, genetic elements and their role in...
Read more
Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. ProgressALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure. The purpose of the amended OTC Annual Report filed today is to include the...
Read moreWOODLAND HILLS, CA / ACCESSWIRE / November 20, 2023 / BioTech Medics, Inc. (OTC PINK:BMCS) is pleased to announce that the Company continues to build the fundamental substructure that will enhance our ability to raise capital to position the organization in a competitive advantage with its calcium carbonate assets to enhance BMCS as a substantial publicly traded firm in this sector. Our website can be found at www.biotechmedics.coAccording to...
Read more
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 17, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related neuromuscular and respiratory diseases, today announced...
Read moreBRIDGEWATER, NJ / ACCESSWIRE / November 17, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions announced today that it will effect a 1-for-25 reverse stock split of its issued and outstanding shares of common stock. The reverse stock split was previously approved by Tharimmune stockholders...
Read more
No Deaths or Pulmonary Embolisms Occurring During the 30 Day MAE PeriodExpected Overall Device-Related Material Adverse Event Rate of 8% for the Fully Enrolled 75 Patient StudySix (6) DVT Related MAEsIRVINE, CA / ACCESSWIRE / November 16, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that positive preliminary device...
Read more
